期刊
CYTOTHERAPY
卷 18, 期 9, 页码 1129-1145出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jcyt.2016.06.008
关键词
adipose tissue; cellular therapy; head and neck cancer; ionizing radiation; mesenchymal stromal cells; normal tissue injury; oral mucositis; radiotherapy
类别
资金
- Lady Davis Institute/Toronto-Dominion Bank studentship
- Fonds de Recherche du Quebec-Sante (FQRS)
- Ride to Conquer Cancer (Jewish General Hospital Foundation)
- FRQS
- Canadian Institutes of Health Research (CIHR) [MOP-15017]
Background aims. Mesenchymal stromal cells (MSCs) have been used to minimize and repair radiation-induced normal tissue injury in the intestine, salivary gland, liver, skin, lungs and cardiac muscle. This study investigated the ability of adipose tissue derived MSCs (aMSCs) to minimize and/or repair single dose radiation-induced oral mucositis (RIOM). Methods. Syngenic phenotypically and functionally characterized BALB/c mouse aMSCs were implanted intraperitoneally in a RIOM mouse model with different dosing protocols. Response was quantified macroscopically, microscopically and by using different histological and clinically relevant parameters. Results. Irradiation at 18 Gy generated a self-resolved single-dose RIOM BALB/c mouse model with 5.6 +/- 0.3 days mean duration (95% confidence interval (CI) 4.233-7.1 days) and 100% survival rate. Intraperitoneal implantation of 5 doses of 2.5 million freshly cultured syngenic aMSCs significantly and reproducibly reduced RIOM ulcer duration to 1.6 +/- 0.3 days (95% CI 0.0233-3.1 days, a 72% reduction in RIOM ulcer duration), ulcer size and ulcer floor epithelial height. The therapeutic benefits were significantly dependent on dose size and frequency, number of doses, and therapy onset time. aMSCs therapy significantly minimized the RIOM-related weight loss, accelerated the weight gain and improved irradiated animals' hydration and nutritional status. aMSCs therapy did not potentiate head and neck cancer in vitro. Conclusions. Syngenic freshly cultured aMSCs significantly minimized and repaired radiation-induced oral mucositis with a 72% reduction in ulcer duration. aMSCs dose size and frequency, number of doses and therapy onset time are the main keys for optimized therapeutic outcome. aMSCs therapy did not stimulate Head and Neck cancer cell growth in-vitro.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据